Supplemental materials for the manuscript entitled "A combination therapy with secukinumab and dupilumab in Netherton syndrome: A prospective pilot study"

Mendeley supplemental methods Mendeley supplemental figure 1. Response to combination therapy with secukinumab and dupilumab for pediatric patients with Netherton syndrome. Clinical images of (A) patient 1, (B) patient 2, and (C) patient 4 during the treatment period. Mendeley supplemental figure 2. Response to combination therapy with secukinumab and dupilumab for pediatric patients with Netherton syndrome. Clinical images of (A) patient 5, (B) patient 6 and (C) patient 7 during the treatment period. Mendeley supplemental figure 3. Changes in hand lesions during combination therapy with secukinumab and dupilumab for patients with Netherton syndrome. Clinical images of (A) patient 4, (B) patient 6 and (C) patient 7 during the treatment period. Mendeley supplemental figure 4. Efficacy of combination therapy with secukinumab and dupilumab in pediatric patients with Netherton syndrome (LOCF). Line charts showing absolute and percent changes in (A) IASI scores, (B) itch NRS scores and (C) CDLQI scores during combination therapy with secukinumab and dupilumab. Missing data were imputed using Last Observation Carried Forward. Abbreviations: LOCF, Last observation carried forward; IASI, Ichthyosis Area Severity Index; NRS, Numeric Rating Scale; CDLQI, Children’s Dermatology Life Quality Index. Mendeley supplemental figure 5. Serum biomarker expression levels of Netherton syndrome. Heatmap presenting the median biomarker expression levels and fold changes among the HC (n=7), NS (n=6) and AD (n=8) groups. These expression values were transformed into z score, which were restricted to values between –1 and 1. *P